Navigation Links
Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial
Date:3/31/2009

Central Texas man receives groundbreaking therapy days after heart attack

AUSTIN, Texas, March 31 /PRNewswire/ -- On March 30, the Heart Hospital of Austin treated the first patient in the world enrolled in a groundbreaking Phase II study designed to test the effectiveness and safety of administering adult stem cells intravenously to repair damaged heart tissue after a heart attack.

Dr. Roger Gammon, a cardiologist with Austin Heart cardiology group treated a 58-year-old Central Texas man with the experimental adult stem cell treatment, just days after his first heart attack.

"We are excited to be the first to treat a patient in this groundbreaking study and to lead the way in this important research," states Dr. Gammon "Austin Heart and the Heart Hospital of Austin were selected because of their proven history of excellence in cardiovascular research and strong performance in the earlier Phase I trial," Gammon adds.

Prochymal(R) is being evaluated for its ability to treat heart damage caused by a heart attack. The active ingredient in the new treatment is adult Mesenchymal Stem Cells (MSCs). The cells in the drug are from normal, healthy adult volunteer donors and are not from a fetus, embryo or animal. MSCs have the ability to develop into other types of cells and generate new tissue, including heart muscle. Prochymal(R) is a product of Osiris Therapeutics, Inc.

"There's a lot of enthusiasm in the cardiovascular community about the potential of stem cell therapies for treating heart disease. Earlier studies have established confidence in the safety of the therapy, but more research is needed to study its effectiveness," states Gammon.

In this prospective, double-blind, placebo-controlled Phase II study, Heart Hospital of Austin and Austin Heart researchers will study patients to determine the effectiveness and safety of Prochymal(R) for treating heart damage resulting from a heart attack. Heart Hospital of Austin is one of approximately 40 institutions in the United States and Canada participating in the study. Patients that participate in the study must receive the treatment within seven days of a heart attack. The stem cell treatment is administered intravenously and typically takes less than an hour to complete.

Prochymal(R) is currently an investigational therapy and is not yet approved by the Food and Drug Administration.

After a Heart Attack:

In 2009 alone, more than half a million Americans will have their first attack. According to the American Heart Association, 18% percent of men and 35% of women will have another heart attack within six years of their event.


'/>"/>
SOURCE Heart Hospital of Austin
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. ATS Medical Expands Open Pivot Heart Valve Offerings
3. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
4. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
5. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
8. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
9. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
10. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):